291-300 of 312 results
Full Federal Court overturns decision allowing patent term extension of 'Swiss-style' claims
The Full Federal Court has unanimously held that patent term extensions are not available for second medical use claims involving the use of recombinant DNA technology This decision overturns a controversial finding of the Administrative Appeals Tribunal last year and means that any patent term ...
Government responds to Productivity Commission's IP inquiry
The Federal Government has released its response to the recommendations proposed by the Productivity Commission following its inquiry into Australias IP arrangements ...
Comply or say bye to your franchise!
With the new Franchising Code of Conduct and civil pecuniary penalties set to commence in 2015 a recent Full Federal Court decision is a timely warning to franchising parties to ensure their practices comply with the Code ...
Scintilla: Intellectual Property in Review
The Allens IP blog Scintilla provides regular insights and analysis on intellectual property law We have published a selection of blog posts in a handy digest for clients In this edition we cover the latest issues in patents trade marks copyright designs and international issues ...
It's crunch time! Changes to the Franchising Code are nigh
The long-anticipated changes to the Franchising Code of Conduct are scheduled to take effect on 1 January 2015 Partners Tim Golder and Andrew Wiseman and Lawyer Nadia Guadagno report on the significant changes ...
Trade mark owners beware
The Full Federal Court has put trademark owners in Australia making it clear that when trade mark applications are filed in the incorrect name, the defect is fatal. Accordingly, it is vital that trade mark owners conduct a critical analysis of their trade mark portfolios and ensure that valid rights ...
Protecting innovation without patents - data exclusivity and market exclusivity
Developments in patent law and the consequential limitations on patentability for biologic medicines mean that data exclusivity and market exclusivity can be the primary protection afforded to originator biologic medicines This is most stark in the US where patent protection for biologic medicines ...
Full Court comes down hard on business method patent, but software remains patentable
In an eagerly awaited appeal decision in emRPL Central v The Commissioner of Patentsem the Full Federal Court has decided that the evidence-gathering method the subject of RPL Centrals innovation patent was a mere scheme abstract idea or business method that did not constitute patentable subject ...
Patent examination guidelines in the wake of Myriad
Following public consultation on proposed examination guidelines issued on 16 October 2015 the Commissioner of Patents has established a revised examination practice taking into account the High Courts decision in emDArcy v Myriad Genetics Incem Dr Trevor Davies Partner at Allens Patent amp Trade ...
Not quite business as usual - IP Australia takes pragmatic view of Myriad
IP Australia has taken a pragmatic approach to the Myriad decision that will give comfort to Australias biotechnology industry and research organisations that they can continue to carry out biological RD and be able to obtain patent protection for innovation in Australia Partner Dr Trevor Davies ...